Assenagon Asset Management S.A. Lowers Holdings in Evolus, Inc. (NASDAQ:EOLS)

Assenagon Asset Management S.A. lessened its stake in Evolus, Inc. (NASDAQ:EOLS) by 54.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 435,453 shares of the company’s stock after selling 520,102 shares during the quarter. Assenagon Asset Management S.A. owned 0.69% of Evolus worth $4,807,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. Barclays PLC raised its position in Evolus by 268.0% in the 3rd quarter. Barclays PLC now owns 93,662 shares of the company’s stock worth $1,518,000 after buying an additional 68,213 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Evolus by 173.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after buying an additional 265,635 shares during the last quarter. Armistice Capital LLC purchased a new position in Evolus in the 2nd quarter worth about $3,906,000. Jane Street Group LLC grew its stake in shares of Evolus by 47.0% during the 3rd quarter. Jane Street Group LLC now owns 91,899 shares of the company’s stock valued at $1,489,000 after purchasing an additional 29,396 shares during the period. Finally, Lord Abbett & CO. LLC grew its stake in shares of Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after purchasing an additional 188,685 shares during the period. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, November 7th.

Evolus Stock Down 0.9 %

Shares of EOLS opened at $10.51 on Tuesday. The stock has a market capitalization of $665.49 million, a price-to-earnings ratio of -11.55 and a beta of 1.32. Evolus, Inc. has a 1 year low of $9.25 and a 1 year high of $17.82. The business’s 50 day simple moving average is $11.65 and its 200-day simple moving average is $13.73. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.